NMRA

Neumora Therapeutics Inc

0.4000

Oct 23 • 5:59 AM ET -0.0057 (-1.40%)

Healthcare Biotechnology USA Micro NASD

Peers: ANRO AXSM SPTX DFTX HELP NERV MPLT GHRS DRUG VTGN

| Held by: VTI IWM VXF IWO VTWO SCHA IBB IWC DFAS VHT

Index	RUT
Market Cap	75.16M
Enterprise Value	11.58M
Income	-212.74M
Sales	0.00M
Book/sh	0.24
Cash/sh	0.62
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	96
IPO	Sep 15, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.68
P/C	0.64
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.50
Current Ratio	4.50
Debt/Eq	1.20
LT Debt/Eq	1.19
Option/Short	Yes / Yes

EPS (ttm)	-1.23
EPS next Y	-0.64
EPS next Q	-0.20
EPS this Y	37.34%
EPS next Y	30.06%
EPS next 5Y	22.14%
EPS past 3/5Y	-18.95% -17.29%
Sales past 3/5Y	- -
EPS Y/Y TTM	21.31%
Sales Y/Y TTM	-
EPS Q/Q	28.64%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	4.21% -

Insider Own	57.80%
Insider Trans	-0.42%
Inst Own	26.95%
Inst Trans	3.55%
ROA	-121.89%
ROE	-187.11%
ROIC	-218.26%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-17.14%
SMA50	-56.19%
SMA200	-78.08%
Trades

Shs Outstand	186.85M
Shs Float	79.28M
Short Float	8.44%
Short Ratio	4.75
Short Interest	6.69M
52W High	3.65 -89.04%
52W Low	0.32 26.82%
Volatility	13.69% 14.38%
ATR (14)	0.07
RSI (14)	28.07
Beta	3.06
Rel Volume	0.00
Avg Volume	1.41M
Volume	263

Perf Week	-15.58%
Perf Month	-43.11%
Perf Quarter	-75.90%
Perf Half Y	-82.22%
Perf YTD	-77.65%
Perf Year	-82.68%
Perf 3Y	-95.91%
Perf 5Y	-
Perf 10Y	-
Recom	1.50
Target Price	6.67
Prev Close	0.41
Price	0.40
Change %	-1.40%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-16-26	Reiterated	Needham	Buy	$8 → $5
Jun-16-26	Reiterated	H.C. Wainwright	Buy	$18 → $7
Feb-17-26	Upgrade	William Blair	Mkt Perform → Outperform
Jan-12-26	Initiated	Leerink Partners	Outperform	$8
Dec-01-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$7
Oct-27-25	Upgrade	Guggenheim	Neutral → Buy	$14
Sep-16-25	Downgrade	JP Morgan	Neutral → Underweight
Apr-02-25	Downgrade	BofA Securities	Buy → Underperform	$1
Mar-10-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-07-25	Downgrade	Stifel	Buy → Hold	$6 → $2
Mar-07-25	Downgrade	Guggenheim	Buy → Neutral
Jan-02-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$29 → $4
Nov-05-24	Downgrade	JP Morgan	Overweight → Neutral	$18 → $15
Oct-01-24	Initiated	H.C. Wainwright	Buy	$30
Jul-22-24	Initiated	Needham	Buy	$23
Jul-08-24	Initiated	Mizuho	Outperform	$20
Dec-12-23	Initiated	Deutsche Bank	Hold	$13
Oct-10-23	Initiated	William Blair	Outperform	$26
Oct-10-23	Initiated	Stifel	Buy	$26
Oct-10-23	Initiated	RBC Capital Mkts	Outperform	$24

Show Previous Ratings

Sep-18-26 11:46AM	Biotech Options Buzz: UTHR, NMRA, EWTX (Schaeffer's Research)
Aug-14-26 07:00AM	Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) -7.51%
Jul-27-26 07:00AM	Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026 (GlobeNewswire) +11.41%
Jun-16-26 11:58AM	Three pivotal MDD trial failures for Neumora lead to staffing cuts (Clinical Trials Arena) +70.59%
05:08AM	Neumora depression drug fails; EnGene to cut 50% of staff (BioPharma Dive)
01:21PM	Loading…
Jun-15-26 01:21PM	NMRA Stock On Track For Worst Day In 1.5 Years Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials (Stocktwits) -48.62%
09:28AM	Neumora Ends Depression Drug Programme and Announces Workforce Reduction (NMRA) (InvestorsHub)
08:00AM	Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update (GlobeNewswire)
May-12-26 04:05PM	Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) -6.32%
May-07-26 07:00AM	Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) -16.74%
Apr-06-26 07:00AM	Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire) +6.00%
Mar-30-26 09:01PM	Neumora Therapeutics Inc (NMRA) Q4 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com) -17.17%
06:53AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-16-26 07:00AM	Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026 (GlobeNewswire)
Mar-09-26 08:11PM	Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity (Insider Monkey) +6.62%
05:39AM	Loading…
Mar-04-26 05:39AM	Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511 (Insider Monkey)
Feb-17-26 02:32PM	Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment (Benzinga) +10.62%
Feb-14-26 10:04AM	Neumora Therapeutics Highlights NMRA-511 AD Agitation Signal, Maps Higher-Dose Plan for 2026 (MarketBeat)
Feb-04-26 07:00AM	Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-08-26 04:10PM	How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine (Investor's Business Daily)
Jan-05-26 06:35AM	Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones (GlobeNewswire)
06:30AM	Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation (GlobeNewswire)
Jan-03-26 06:19AM	RBC Sees Upside Potential in Neumora Therapeutics (NMRA) (Insider Monkey)
Nov-07-25 07:26PM	MapLight Therapeutics, Gold Royalty, and More Stocks See Action From Activist Investors (Barrons.com) +9.77%
Nov-06-25 07:00AM	Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-25 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire)
Oct-30-25 11:29PM	Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating (Insider Monkey) +17.20%
Oct-27-25 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898 (GlobeNewswire)
06:30AM	Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model (GlobeNewswire)
Oct-01-25 07:00AM	Neumora Therapeutics to Host Virtual R&D Day on October 27 (GlobeNewswire)
09:40AM	Loading…
Sep-17-25 09:40AM	Apple initiated, Hershey upgraded: Wall Streets top analyst calls (TipRanks)
Sep-16-25 09:35AM	Apple initiated, Hershey upgraded: Wall Street's top analyst calls (The Fly)
Sep-02-25 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in September (GlobeNewswire)
Aug-20-25 12:13AM	Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861 (Insider Monkey)
Aug-08-25 05:07AM	Elevidys sales weaken; Neumora gets into obesity (BioPharma Dive) -11.52%
Aug-06-25 04:05PM	Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-25 10:23AM	Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating (Insider Monkey)
Jul-23-25 07:00AM	Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 (GlobeNewswire)
Jul-20-25 12:35AM	Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating (Insider Monkey)
Jul-09-25 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 (GlobeNewswire) +13.12%
May-13-25 03:10AM	Neumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ... (GuruFocus.com)
May-12-25 04:01PM	Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-25 07:00AM	Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (GlobeNewswire)
Apr-22-25 02:49AM	Former Neumora CEO to lead Galapagos spinout (BioPharma Dive) +6.82%
Apr-21-25 04:10PM	Galapagos Announces Executive Leadership Updates (GlobeNewswire)
Mar-18-25 05:45AM	Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Mar-07-25 12:26PM	J&J drops Phase III MDD programme due to lack of efficacy (Clinical Trials Arena)
07:08AM	J&J scraps depression testing for potential blockbuster drug (BioPharma Dive)
Mar-04-25 08:30AM	Neumora Therapeutics to Present at Leerink Global Healthcare Conference (GlobeNewswire)
06:25AM	Neumora bids farewell to R&D head; Biohavens one step forward, one step back data (BioPharma Dive)
Mar-03-25 07:00AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -9.94%
Feb-28-25 05:45AM	Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Feb-26-25 08:46PM	Robbins LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors With Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses (PR Newswire)
Feb-25-25 05:45AM	Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Feb-18-25 05:45AM	Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Feb-13-25 10:33AM	Neumora shakes up its C-suite; Biogen cuts early-stage pipeline (BioPharma Dive)
07:00AM	Neumora Therapeutics Announces Leadership Transition (GlobeNewswire)
Feb-11-25 05:45AM	Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire) -6.18%
Jan-04-25 08:00AM	Neumora shares look oversold after 80% drop, says Mizuho (TipRanks)
Jan-03-25 07:20AM	Neumora Therapeutics navacaprant did not meet primary endpoint in depression (TipRanks) +10.15%
Jan-02-25 05:07PM	Results are in for a new depression drug trial, and they're cratering this stock (Quartz) -81.42%
04:22PM	Neumora Therapeutics Stock Crashes 81% After Depression Drug Flops (Investor's Business Daily)
01:28PM	Neumora Nosedives 80% At Pre-Market on Failed Depression Drug Trial (Insider Monkey)
01:07PM	Neumora shares sink following Phase III flop in MDD (Pharmaceutical Technology)
12:00PM	Top Stock Movers Now: Uber, Unity Software, Tesla, and More (Investopedia)
10:47AM	Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals (Investopedia)
09:59AM	Stock in Biotech Neumora Plunges 80% as Depression Drug Fails (Barrons.com)
09:54AM	Neumora Plunges After Major Depression Drug Fails in Study (Bloomberg)
08:30AM	Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials (Benzinga)
07:00AM	Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder (GlobeNewswire)
Nov-19-24 08:53AM	Neumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To Explode (Insider Monkey)
Nov-12-24 07:00AM	Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -17.08%
Nov-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) +6.72%
Oct-29-24 07:00AM	Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (GlobeNewswire)
Aug-14-24 07:00AM	Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders (GlobeNewswire)
Aug-06-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-01-24 01:00AM	10 clinical trials to watch in the second half of 2024 (BioPharma Dive)
Jun-20-24 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation (GlobeNewswire)
May-14-24 08:52AM	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression (MT Newswires) +6.92%
07:00AM	Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression (GlobeNewswire)
May-07-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024 (InvestorPlace)
10:20AM	Neumora Therapeutics Shares Fall as Q1 Loss Narrows (MT Newswires)
07:00AM	Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in May (GlobeNewswire)
Apr-16-24 11:28AM	Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug (Zacks)
Apr-15-24 04:20PM	Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug (Investor's Business Daily) -17.48%
12:17PM	Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday? (Benzinga)
08:45AM	Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today? (InvestorPlace)
07:47AM	Neumoras schizophrenia drug hit with clinical hold (BioPharma Dive)
06:36AM	U.S. FDA places clinical hold on Neumora's schizophrenia drug study (Reuters)
06:30AM	Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study (GlobeNewswire)
Mar-13-24 07:00AM	Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days (GlobeNewswire) -14.64%
Mar-07-24 02:52PM	NMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jan-22-24 07:00AM	Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer (GlobeNewswire) +9.89%
Jan-10-24 08:32AM	Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick (Zacks)
Jan-02-24 07:00AM	Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-17-23 12:35PM	7 Stocks with Strong Insider Buying: December 2023 (InvestorPlace)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Aurora Daljit Singh	See Remarks	Aug 20 '26	Option Exercise	0.72	67,741	48,774	116,491	Aug 21 07:10 PM
Aurora Daljit Singh	See Remarks	Aug 20 '26	Option Exercise	0.72	66,711	48,032	66,711	Aug 21 07:10 PM
Aurora Daljit Singh	See Remarks	Aug 21 '26	Option Exercise	0.72	21,055	15,160	21,055	Aug 21 07:10 PM
Aurora Daljit Singh	See Remarks	Aug 21 '26	Option Exercise	0.72	20,553	14,798	69,303	Aug 21 07:10 PM
Aurora Daljit Singh	See Remarks	Aug 20 '26	Sale	1.51	67,741	102,587	48,750	Aug 21 07:10 PM
Aurora Daljit Singh	See Remarks	Aug 20 '26	Sale	1.51	66,711	101,000	0	Aug 21 07:10 PM
Aurora Daljit Singh	See Remarks	Aug 21 '26	Sale	1.60	21,055	33,600	0	Aug 21 07:10 PM
Aurora Daljit Singh	See Remarks	Aug 21 '26	Sale	1.59	20,553	32,780	48,750	Aug 21 07:10 PM
Aurora Daljit Singh	Officer	Aug 21 '26	Proposed Sale	1.60	41,608	66,380		Aug 21 04:34 PM
Aurora Daljit Singh	Officer	Aug 20 '26	Proposed Sale	1.51	134,452	203,584		Aug 20 04:22 PM
Aurora Daljit Singh	See Remarks	Aug 17 '26	Option Exercise	0.72	57,670	41,522	140,440	Aug 19 07:17 PM
Aurora Daljit Singh	See Remarks	Aug 17 '26	Option Exercise	0.72	55,016	39,612	55,016	Aug 19 07:17 PM
Aurora Daljit Singh	See Remarks	Aug 18 '26	Option Exercise	0.72	34,987	25,191	34,987	Aug 19 07:17 PM
Aurora Daljit Singh	See Remarks	Aug 18 '26	Option Exercise	0.72	34,162	24,597	82,912	Aug 19 07:17 PM
Aurora Daljit Singh	See Remarks	Aug 19 '26	Option Exercise	0.72	31,000	22,320	79,750	Aug 19 07:17 PM
Aurora Daljit Singh	See Remarks	Aug 19 '26	Option Exercise	0.72	30,918	22,261	30,918	Aug 19 07:17 PM
Aurora Daljit Singh	See Remarks	Aug 17 '26	Sale	1.50	91,690	137,352	48,750	Aug 19 07:17 PM
Aurora Daljit Singh	See Remarks	Aug 17 '26	Sale	1.50	55,016	82,783	0	Aug 19 07:17 PM
Aurora Daljit Singh	See Remarks	Aug 18 '26	Sale	1.59	34,987	55,486	0	Aug 19 07:17 PM
Aurora Daljit Singh	See Remarks	Aug 18 '26	Sale	1.58	34,162	54,137	48,750	Aug 19 07:17 PM
Aurora Daljit Singh	See Remarks	Aug 19 '26	Sale	1.65	31,000	51,029	48,750	Aug 19 07:17 PM
Aurora Daljit Singh	See Remarks	Aug 19 '26	Sale	1.65	30,918	50,888	0	Aug 19 07:17 PM
Aurora Daljit Singh	Officer	Aug 19 '26	Proposed Sale	1.65	61,918	101,917		Aug 19 04:19 PM
Aurora Daljit Singh	Officer	Aug 18 '26	Proposed Sale	1.59	69,149	109,622		Aug 18 04:32 PM
Aurora Daljit Singh	Officer	Aug 17 '26	Proposed Sale	1.50	146,706	220,135		Aug 17 05:25 PM
Aurora Daljit Singh	See Remarks	Feb 17 '26	Sale	3.56	6,165	21,917	82,770	Feb 19 05:07 PM
Pinto Joshua	President	Feb 17 '26	Sale	3.54	5,967	21,093	57,783	Feb 19 05:06 PM
BERNS PAUL L	See Remarks	Feb 17 '26	Sale	3.51	9,819	34,459	7,395,185	Feb 19 05:05 PM
Milligan Michael Lee	See Remarks	Feb 17 '26	Sale	3.56	1,436	5,119	21,034	Feb 19 05:04 PM
Pinto Joshua	Officer	Feb 17 '26	Proposed Sale	3.54	5,967	21,093		Feb 17 04:25 PM
BERNS PAUL L	Officer	Feb 17 '26	Proposed Sale	3.51	9,819	34,459		Feb 17 04:24 PM
Aurora Daljit Singh	Officer	Feb 17 '26	Proposed Sale	3.56	6,165	21,917		Feb 17 04:23 PM
Milligan Michael Lee	Officer	Feb 17 '26	Proposed Sale	3.56	1,436	5,119		Feb 17 04:21 PM
Aurora Daljit Singh	See Remarks	Nov 11 '25	Sale	2.68	114,703	307,026	0	Nov 13 04:39 PM
Aurora Family Trust	Director	Nov 11 '25	Proposed Sale	2.68	114,703	307,027		Nov 12 07:54 PM
Burow Kristina	Director	Oct 27 '25	Buy	2.61	1,915,700	4,999,977	6,046,907	Oct 29 07:22 PM
ARCH Venture Partners XII, LLC	10% Owner	Oct 27 '25	Buy	2.61	1,915,700	4,999,977	6,046,907	Oct 29 07:21 PM
ARCH Venture Partners X, LLC	10% Owner	Oct 27 '25	Buy	2.61	1,915,700	4,999,977	6,046,907	Oct 29 07:19 PM

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. The firm offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. It focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Executive ChairmanMr. Paul L. Berns

Chief Operationg & Development officerDr. Daljit Singh Aurora Pharm.D.

CFO & Principal Accounting OfficerMr. Michael Lee Milligan

Chief Scientific OfficerDr. Nicholas Brandon Ph.D.

Chief Information OfficerMr. Pablo Gersberg

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NMRA

Neumora Therapeutics Inc

Upgrade your Finviz experience